ET190L1-Artemis™ Cell Therapy Results in Durable Disease Remissions with No Cytokine Release Syndrome or Neurotoxicity in Patients with Relapsed and Refractory B-Cell Lymphoma

被引：1

作者：

Ying, Zhitao ^{[1
]}

Long, Li ^{[2
]}

Liu, Hong ^{[3
]}

Song, Yuqin ^{[1
]}

Rizzieri, David A. ^{[4
,5
]}

Nejadnik, Bijan ^{[6
]}

Zhu, Jun ^{[1
]}

Liu, Cheng ^{[3
]}

机构：

[1] Peking Univ, Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Lymphoma,Minist Educ, Beijing, Peoples R China

[2] Eureka Therapeut Inc, Lafayette, CA USA

[3] Eureka Therapeut Inc, Emeryville, CA USA

[4] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27710 USA

[5] Duke Univ, Sch Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA

[6] Eureka Therapeut Inc, Clin Dev, Emeryville, CA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-113163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1689

引用

页数：3

共 50 条

[1] ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study.
Ying, Zhi Tao
Long, Li
Liu, Hong
Zhang, Mei
He, Pengcheng
Rizzieri, David
Song, Yuqin
Nejadnik, Bijan
Zhu, Jun
Liu, Cheng
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Cytokine Release Syndrome and Neurotoxicity after Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: Is There an Association with Bridging Radiotherapy?
Yegya-Raman, N.
Wright, C. M.
Zhang, S.
Baron, J.
LaRiviere, M. J.
Gerson, J. N.
Nasta, S. D.
Barta, S.
Chong, E. A.
Landsburg, D. J.
Svoboda, J.
Schuster, S.
Xiao, Y.
Maity, A.
Paydar, I.
Plastaras, J. P.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S84 - S85
[3] Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival
Shouval, Roni
Strouse, Christopher
Kim, Soyoung
Oloyede, Temitope
Ahmed, Sairah
Awan, Farrukh T.
Bachanova, Veronika
Badar, Talha
Barba, Pere
Beitinjaneh, Amer M.
Cashen, Amanda F.
Dholaria, Bhagirathbhai
Elsawy, Mahmoud
Ganguly, Siddhartha
Geethakumari, Praveen Ramakrishnan
Greenbaum, Uri
Hashmi, Hamza
Hill, Laquisa C.
Jain, Michael D.
Jain, Tania
Kebriaei, Partow
Kittai, Adam S.
Locke, Frederick L.
Lulla, Premal D.
Mead, Elena
McGuirk, Joseph P.
Mussetti, Alberto
Nishihori, Taiga
Olson, Amanda L.
Pennisi, Martina
Perales, Miguel-Angel
Riedell, Peter A.
Saber, Wael
Mirza, Sayeef
Magalhaes-Silverman, Margarida
Shpall, Elizabeth J.
Sorror, Mohamed
Wudhikarn, Kitsada
Turtle, Cameron J.
Pasquini, Marcelo
Moskop, Amy
BLOOD, 2023, 142
[4] Managing Cytokine Release Syndrome and Neurotoxicity with Step-Up Dosing of Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Bartlett, Nancy L.
Sehn, Laurie H.
Assouline, Sarit
Bosch, Francesc
Diefenbach, Catherine M.
Flinn, Ian
Hong, Jung Yong
Kim, Wonseog S.
Matasar, Matthew
Nastoupil, Loretta
Schuster, Stephen J.
Shadman, Mazyar
Yoon, Sung-Soo
Bender, Brendan
Chu, Wayne
Hernandez, Genevive
Kwan, Antonia
McCall, Bruce
Sison, Iris
Wang, Cunlin
Wei, Michael C.
Yin, Shen
Yousefi, Kasra
Budde, Elizabeth L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S247 - S247
[5] Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Inoue, Yu
Fujino, Takahiro
Chinen, Shotaro
Niiyama-Uchibori, Yui
Ide, Daisuke
Kawata, Moe
Hashimoto, Keiko
Takimoto-Shimomura, Tomoko
Nakayama, Ai
Tsukamoto, Taku
Mizutani, Shinsuke
Shimura, Yuji
Hirano, Shigeru
Kuroda, Junya
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (05)
[6] Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
Matasar, Matthew J.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (11.5): : 1327 - 1330
[7] Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma
Badar, Talha
Johnson, Bryon D.
Hamadani, Mehdi
BONE MARROW TRANSPLANTATION, 2021, 56 (03) : 683 - 685
[8] Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma
Talha Badar
Bryon D. Johnson
Mehdi Hamadani
Bone Marrow Transplantation, 2021, 56 : 683 - 685
[9] Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients
Bachanova, Veronika
Westin, Jason
Tam, Constantine
Borchmann, Peter
Jaeger, Ulrich
McGuirk, Joseph
Holte, Harald
Waller, Edmund
Jaglowski, Samantha
Bishop, Michael
Andreadis, Charalambos
Foley, Ronan S.
Fleury, Isabelle
Teshima, Takanori
Mielke, Stephan
Salles, Gilles
Ho, P. Joy
Izutsu, Koji
Maziarz, Richard
Van Besien, Koen
Kersten, Marie Jose
Wagner-Johnston, Nina
Kato, Koji
Corradini, Paolo
Han, Xia
Agoulnik, Sergei
Chu, Jufen
Eldjerou, Lamis
Pacaud, Lida
Schuster, Stephen
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S251 - S252
[10] Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
Bartlett, Nancy L.
Sehn, Laurie Helen
Assouline, Sarit E.
Bosch, Francesc
Diefenbach, Catherine S. Magid
Flinn, Ian
Hong, Jungyong
Kim, Wonseog S.
Matasar, Matthew J.
Nastoupil, Loretta J.
Schuster, Stephen J.
Shadman, Mazyar
Yoon, Sung-Soo
Bender, Brendan
Kwan, Antonia
Wang Cunlin
Wei, Michael C.
Yin, Shen
Yousefi, Kasra
Budde, L. Elizabeth
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →